Trial Profile
A retrospective, multicenter trial evaluated the efficacy and safety of abiraterone acetate versus enzalutamide versus cabazitaxel in metastatic castration-resistant prostate cancer patients after failure of docetaxel (DOC).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2017
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Cabazitaxel (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 07 Apr 2016 New trial record